drugset / Trial / NCT00746980

Efalizumab in the Treatment of Alopecia, Phase II

NCT00746980

NaSingle-groupOpen-labelTreatment

Summary

Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.

Timeline

Start
2008-08
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject efalizumab Monoclonal antibody 1 mg/kg Subcutaneous

Indications